Innovative Medicine segment income before tax as a percent of sales in the fiscal second quarter of 2026 was 38.1% versus 36.5% for the same period a year ago
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations
The program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on · in our words, not the filing’s